A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

Completed · Phase 1

Conditions studied: Renal Dialysis, Pharmacokinetics

In brief

1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodialysis.

Key facts

Study ID

NCT00730145

Run by

Pfizer

People needed

8

Starts

2008-09-01

Expected to finish

2009-01-01

Last updated by the study team

2010-02-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients receiving regular hemodialysis
• Male or female patients 18 to 65 years

You may not qualify if…

• Severe heart failure
• Renal transplant or renal allograft
• Illicit drug use (with the exception of prescribed sedatives)

Where it is running

• Pfizer Investigational Site — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.